Putting black skin cancer to sleep—for good

February 22, 2018, Max Delbrück Center for Molecular Medicine
Melanoma cells under the microscope. Credit: AG Clemens A. Schmitt, MDC/Charité

An international research team has succeeded in stopping the growth of malignant melanoma by reactivating a protective mechanism that prevents tumor cells from dividing. The team used chemical agents to block the enzymes responsible for erasing epigenetic marks at the DNA. This discovery has potential for use in future combination therapies.

Cellular senescence - a state in which terminally cease to divide - prevents mutated cells from turning into tumors. This natural protective mechanism puts cells into a hibernation-like condition and is controlled by epigenetic tags located on the protein building blocks the DNA is wrapped around. These tags co-control how the genetic information encoded by the DNA is actually used. Cancer cells, however, were now found to deactivate the tags via a mechanism that was hitherto unknown.

An international team of researchers led by Professor Clemens A. Schmitt from Charité - Universitätsmedizin Berlin, the Max Delbrück Center for Molecular Medicine (MDC), and the Berlin Institute of Health (BIH) has now demonstrated that, in , these important are often erased by demethylase enzymes. Genetic or pharmacological inhibition of these enzymes restarts the protective mechanism, explains the team in an article published in the journal Cancer Cell.

Demethylase blockers halt malignant melanoma

The research team conducted its study on almost 500 tissue samples taken from patients with black skin , also known as . In roughly a third of the samples, researchers found a significant increase in the production of the demethylase enzymes able to stop the protective mechanism.

In melanoma cell cultures as well as mice and zebrafish with , the researchers genetically modified the activity of these enzymes. They also used chemical agents to target and block them, which caused the cells to fall into the sleep-like state of senescence, thus stopping them to further divide. The experiment was even successful in mice with implanted human melanoma tissue, which is important information for future applications in patients. One of the agents used is currently explored in clinical trials for the treatment of lung and blood cancer.

In their investigation of melanoma samples from mice, the researchers observed that migrated into the tumor tissue once the senescence process had been reactivated by drugs. These and other important findings would not have been possible without using animal models.

Senescence keeps cancer cells in hibernation

Together with programmed cell death, is one of the body's most important lines of defense against cancer. This epigenetically silences genes that regulate cell division. Methyltransferase enzymes mark histone proteins - the "spools" around which DNA is wrapped. These marks deactivate the section of DNA that is next to the histone. Clemens Schmitt and his team investigated two different demethylase enzymes that are able to counteract this process. Their ability to "erase" these histone marks makes the enzymes crucial for controlling and disabling senescence.

Potential seen for combination therapies

Cellular senescence is an important and welcome avenue for cancer therapies due to its ability to prevent the further growth of tumors. But its functions are not limited to blocking cancer, as Schmitt's research team recently reported in the scientific journal Nature.

Clemens Schmitt believes the immigration of immune cells into the tumor that was observed in the senescence mechanism holds great potential for a new type of combination therapy. "We think the combined use of demethylase blockers and targeted immunotherapy might be extremely effective," reports the clinical oncologist and researcher, who is Vice Director of the Division of Hematology, Oncology and Tumor Immunology in Charité's Medical Department.

These findings are particularly promising for the treatment of melanoma, as this cancer responds poorly to chemotherapy and is better combated with the help of new immunotherapies. Schmitt and his colleagues now want to see how well immunotherapy and senescence-inducing therapy can be combined in clinical trials.

Explore further: Cancer cells that escape from senescence found to have an enhanced capacity to drive tumor growth

More information: Yong Yu et al, Targeting the Senescence-Overriding Cooperative Activity of Structurally Unrelated H3K9 Demethylases in Melanoma, Cancer Cell (2018). DOI: 10.1016/j.ccell.2018.01.002

Related Stories

Cancer cells that escape from senescence found to have an enhanced capacity to drive tumor growth

December 22, 2017
An international team of researchers has found that cancer cells that escape from senescence due to use of chemotherapy have an enhanced capacity to drive tumor growth. In their paper published in the journal Nature, the ...

Another piece to the puzzle in naked mole rats' long, cancer-free life

February 6, 2018
With their large buck teeth and wrinkled, hairless bodies, naked mole rats won't be winning any awards for cutest rodent. But their long life span—they can live up to 30 years, the longest of any rodent—and remarkable ...

Researchers create novel compound targeting melanoma cells

January 4, 2018
An international team of researchers has developed a novel compound that successfully inhibits growth of melanoma cells by targeting specific epigenetic modifying proteins in these cells.

Clipping proteins that package genes may limit abnormal cell growth in tumors

November 21, 2014
Changes to the structure of the protein histone H3.3 may play a key role in silencing genes that regulate cancer cell growth, according to a study led by researchers from the Icahn School of Medicine at Mount Sinai and published ...

Who might benefit from immunotherapy? New study suggests possible marker

January 16, 2018
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments.

New therapeutic approach to fight cancer discovered

September 4, 2013
Resting cancer cells can be selectively destroyed by inhibiting their energy metabolism. This is the recent discovery by researchers at Charité Universitätsmedizin Berlin and the Max Delbrück Center for Molecular Medicine ...

Recommended for you

Daily low-dose aspirin may be weapon against ovarian cancer

July 20, 2018
(HealthDay)— One low-dose aspirin a day could help women avoid ovarian cancer or boost their survival should it develop, two new studies suggest.

Discovery of kidney cancer driver could lead to new treatment strategy

July 19, 2018
University of North Carolina Lineberger Comprehensive Cancer Center scientists have uncovered a potential therapeutic target for kidney cancers that have a common genetic change. Scientists have known this genetic change ...

High fruit and vegetable consumption may reduce risk of breast cancer, especially aggressive tumors

July 19, 2018
Women who eat a high amount of fruits and vegetables each day may have a lower risk of breast cancer, especially of aggressive tumors, than those who eat fewer fruits and vegetables, according to a new study led by researchers ...

Sunscreen reduces melanoma risk by 40 per cent in young people

July 19, 2018
A world-first study led by University of Sydney has found that Australians aged 18-40 years who were regular users of sunscreen in childhood reduced their risk of developing melanoma by 40 percent, compared to those who rarely ...

Analysis of prostate tumors reveals clues to cancer's aggressiveness

July 19, 2018
Using genetic sequencing, scientists have revealed the complete DNA makeup of more than 100 aggressive prostate tumors, pinpointing important genetic errors these deadly tumors have in common. The study lays the foundation ...

Complementary medicine for cancer can decrease survival

July 19, 2018
People who received complementary therapy for curable cancers were more likely to refuse at least one component of their conventional cancer treatment, and were more likely to die as a result, according to researchers from ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.